^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Tumori
    Title:

    Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib

    Published date:
    06/02/2023
    Excerpt:
    Here we report the case of a 68-year-old female with multiple myeloma and an incidental cT1b (9 mm) hormone receptor positive breast cancer lesion that showed a complete pathological response to a three-month combination therapy with Ixazomib, bendamustine and dexamethasone and no signs of disease relapse during the later follow-up.
    Secondary therapy:
    dexamethasone + bendamustine
    DOI:
    10.1177/03008916231176586